Compare Cytokinetics Inc (CYTK) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Funko Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Funko Inc trades at $6.44 (market cap $363.97M). The key difference: Cytokinetics Inc is far larger — about 23.7× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Funko Inc for 33 Days on average.
| CYTK | FNKO | |
|---|---|---|
Market Cap | $8.62B | $363.97M |
Volume | 2,594,626 | 1,422,651 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $7.10 |
52-Week Low | $54.76 | $2.81 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $8.72B | $584.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Funko (FNKO) trades at $6.50, up 3.01% today, with strong technical momentum showing bullish moving average signals. The company reported mixed Q2 2026 results with revenue growth of 7% to $207.7 million and significant EBITDA improvement, though net income remains negative. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 16.6% upside potential from current levels.
Investment outlook balances improving operational metrics against persistent profitability challenges. The stock offers potential upside based on analyst targets and recent earnings beats, but risks include negative net margins, volatile cash flows, and high debt levels that could pressure shareholder returns in a competitive collectibles market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
